{"id":403117,"date":"2020-12-18T17:03:19","date_gmt":"2020-12-18T22:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403117"},"modified":"2020-12-18T17:03:19","modified_gmt":"2020-12-18T22:03:19","slug":"castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","title":{"rendered":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares<\/b><\/p>\n<p>FRIENDSWOOD, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCastle Biosciences, Inc.<b \/>(Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters\u2019 option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were $266.8 million.\n<\/p>\n<p>\nSVB Leerink and Baird acted as joint bookrunning managers in the offering. Canaccord Genuity acted as passive bookrunner and BTIG and Lake Street Capital Markets acted as co-managers in the offering.\n<\/p>\n<p>\nThe securities described above were offered by Castle pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Castle and became effective by rule of the Securities and Exchange Commission (the \u201cSEC\u201d) on December 14, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC\u2019s website located at <span class=\"bwuline\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52351514&amp;newsitemid=20201218005681&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov&amp;index=1&amp;md5=6c208af8d4b45e37a7520cd3dce29cdb\">http:\/\/www.sec.gov<\/a><\/span>. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at <a rel=\"nofollow\" href=\"mailto:syndicate@svbleerink.com\">syndicate@svbleerink.com<\/a>; or Robert W. Baird &amp; Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Ave., Milwaukee, WI 53202, by telephone at (800) 792-2473, or by email at <a rel=\"nofollow\" href=\"mailto:syndicate@rwbaird.com\">syndicate@rwbaird.com<\/a>.\n<\/p>\n<p>\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\n<\/p>\n<p><b>About Castle Biosciences<\/b><\/p>\n<p>\nCastle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201218005681\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201218005681\/en\/<\/a><\/span><\/p>\n<p>\nMedia and Investor Contact:<br \/>\n<br \/>Camilla Zuckero<br \/>\n<br \/>832-835-5158<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:czuckero@castlebiosciences.com\">czuckero@castlebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201218005681\/en\/848079\/3\/CastleLogoColor_Transparent.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc.(Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters\u2019 option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were $266.8 million. SVB Leerink and Baird acted as joint bookrunning managers in the offering. Canaccord Genuity acted &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403117","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc.(Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters\u2019 option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were $266.8 million. SVB Leerink and Baird acted as joint bookrunning managers in the offering. Canaccord Genuity acted &hellip; Continue reading &quot;Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-18T22:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\",\"datePublished\":\"2020-12-18T22:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"wordCount\":433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"name\":\"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-18T22:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","og_description":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc.(Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters\u2019 option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were $266.8 million. SVB Leerink and Baird acted as joint bookrunning managers in the offering. Canaccord Genuity acted &hellip; Continue reading \"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-18T22:03:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","datePublished":"2020-12-18T22:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"wordCount":433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","name":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-18T22:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201218005681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403117"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}